XML 89 R77.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION - Schedule of Reportable Segments (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2025
USD ($)
segment
Mar. 31, 2024
USD ($)
Segment Reporting [Abstract]    
Number of reportable segments | segment 3  
Financial information regarding the Company's reportable segments    
Net Sales $ 887,305 $ 915,448
Selling, Research & Development and Administrative: 155,277 152,780
Restructuring Initiatives (2,042) (3,480)
Net unrealized investment (loss) gain (1,096) 592
Depreciation and amortization (65,647) (64,349)
Interest Expense (11,351) (10,175)
Interest Income 2,814 2,898
Income before Income Taxes 106,015 104,318
Optimization initiative    
Financial information regarding the Company's reportable segments    
Restructuring Initiatives (2,042) (3,497)
Prior year initiatives    
Financial information regarding the Company's reportable segments    
Restructuring Initiatives 0 17
Aptar Pharma    
Financial information regarding the Company's reportable segments    
Net Sales 409,467 407,293
Aptar Beauty    
Financial information regarding the Company's reportable segments    
Net Sales 305,707 327,320
Aptar Closures    
Financial information regarding the Company's reportable segments    
Net Sales 172,131 180,835
Operating segment    
Financial information regarding the Company's reportable segments    
Net Sales 895,919 925,067
Adjusted EBITDA 206,848 200,473
Depreciation and amortization (64,785) (63,561)
Operating segment | Aptar Pharma    
Financial information regarding the Company's reportable segments    
Net Sales 409,697 407,490
Cost of Sales (exclusive of depreciation and amortization): 205,137 213,747
Selling, Research & Development and Administrative: 62,483 61,593
Other Segment Items: (603) (225)
Adjusted EBITDA 142,450 132,178
Restructuring Initiatives (190) (24)
Depreciation and amortization (31,148) (28,802)
Operating segment | Aptar Beauty    
Financial information regarding the Company's reportable segments    
Net Sales 312,301 334,880
Cost of Sales (exclusive of depreciation and amortization): 224,048 237,972
Selling, Research & Development and Administrative: 46,412 48,628
Other Segment Items: (1,891) (414)
Adjusted EBITDA 37,138 41,134
Restructuring Initiatives (395) (2,710)
Depreciation and amortization (20,062) (21,228)
Operating segment | Aptar Closures    
Financial information regarding the Company's reportable segments    
Net Sales 173,921 182,697
Cost of Sales (exclusive of depreciation and amortization): 122,391 131,336
Selling, Research & Development and Administrative: 23,012 22,665
Other Segment Items: (532) (327)
Adjusted EBITDA 27,260 27,161
Restructuring Initiatives (1,352) (760)
Depreciation and amortization (13,575) (13,531)
Intersegment    
Financial information regarding the Company's reportable segments    
Net Sales (8,614) (9,619)
Intersegment | Aptar Pharma    
Financial information regarding the Company's reportable segments    
Net Sales (230) (197)
Intersegment | Aptar Beauty    
Financial information regarding the Company's reportable segments    
Net Sales (6,594) (7,560)
Intersegment | Aptar Closures    
Financial information regarding the Company's reportable segments    
Net Sales (1,790) (1,862)
Corporate & Other    
Financial information regarding the Company's reportable segments    
Adjusted EBITDA (23,511) (21,641)
Restructuring Initiatives (105) 14
Depreciation and amortization $ (862) $ (788)